Literature DB >> 19027009

ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained.

Shi-Ying Cai1, Samir Gautam, Trong Nguyen, Carol J Soroka, Christoph Rahner, James L Boyer.   

Abstract

BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis 1 (PFIC1) results from mutations in ATP8B1, a putative aminophospholipid flippase. Conflicting hypotheses have been proposed for the pathogenesis of PFIC1. The aim of this study was to determine whether ATP8B1 deficiency produces cholestasis by altering the activity of the farnesoid X receptor (FXR) or by impairing the structure of the canalicular membrane.
METHODS: ATP8B1/Atp8b1 was knocked down in human and rat hepatocytes and Caco2 cells using adenoviral and oligonucleotide small interfering RNAs.
RESULTS: ATP8B1 messenger RNA and protein expression was greatly reduced in human and rat cells. In contrast, FXR expression and several FXR-dependent membrane transporters (bile salt export pump [BSEP], multidrug resistance-associated protein [MRP] 2) were unchanged at messenger RNA or protein levels in ATP8B1-deficient cells, whereas Mrp3 and Mrp4 were up-regulated in rat hepatocytes. FXR activity remained intact in these cells, as evidenced by 6alpha-ethyl chenodeoxycholic acid-mediated induction of small heterodimer partner, BSEP, and multidrug-resistant protein (MDR) 3/Mdr2. Fluorescent substrate excretion assays indicate that Bsep function was significantly reduced in Atp8b1-deficient rat hepatocytes, although Bsep remained localized to the canalicular membrane. Exposure to the hydrophobic bile acid CDCA resulted in focal areas of canalicular membrane disruption by electron microscopy and luminal accumulation of NBD-phosphatidylserine, consistent with the function of Atp8b1 as an aminophospholipid flippase.
CONCLUSIONS: ATP8B1 deficiency predisposes to cholestasis by favoring bile acid-induced injury in the canalicular membrane but does not directly affect FXR expression, which may occur in PFIC1 as a secondary phenomenon associated with cholestasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027009      PMCID: PMC3439851          DOI: 10.1053/j.gastro.2008.10.025

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Cytokines and the progression of liver damage in experimental bile duct ligation.

Authors:  M Plebani; M P Panozzo; D Basso; M De Paoli; R Biasin; D Infantolino
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-04       Impact factor: 2.557

Review 2.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

3.  Progressive intrahepatic cholestasis (Byler's disease): case report.

Authors:  R De Vos; C de Wolf-Peeters; V Desmet; E Eggermont; K Van Acker
Journal:  Gut       Date:  1975-12       Impact factor: 23.059

4.  Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation.

Authors:  Christine Demeilliers; Emmanuel Jacquemin; Véronique Barbu; Martine Mergey; François Paye; Laura Fouassier; Nicolas Chignard; Chantal Housset; Nour-Eddine Lomri
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

5.  The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor.

Authors:  Tamara Frankenberg; Tamir Miloh; Frank Y Chen; Meena Ananthanarayanan; An-Qiang Sun; Natarajan Balasubramaniyan; Irwin Arias; Kenneth D R Setchell; Frederick J Suchy; Benjamin L Shneider
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

6.  Familial intrahepatic cholestasis 1: studies of localization and function.

Authors:  P Ujhazy; D Ortiz; S Misra; S Li; J Moseley; H Jones; I M Arias
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

7.  Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver.

Authors:  Yong Wu; Xiaoxue Zhang; Fawzia Bardag-Gorce; Rose C V Robel; Jonathan Aguilo; Lixin Chen; Ying Zeng; Kelly Hwang; Samuel W French; Shelly C Lu; Yu-Jui Y Wan
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

8.  Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1.

Authors:  Luis Alvarez; Paloma Jara; Elena Sánchez-Sabaté; Loreto Hierro; Javier Larrauri; María C Díaz; Carmen Camarena; Angela De la Vega; Esteban Frauca; Eduardo López-Collazo; Pablo Lapunzina
Journal:  Hum Mol Genet       Date:  2004-08-18       Impact factor: 6.150

9.  ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity.

Authors:  Coen C Paulusma; Dineke E Folmer; Kam S Ho-Mok; D Rudi de Waart; Petra M Hilarius; Arthur J Verhoeven; Ronald P J Oude Elferink
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation.

Authors:  Romi Ghose; Tracy L Zimmerman; Sundararajah Thevananther; Saul J Karpen
Journal:  Nucl Recept       Date:  2004-08-16
View more
  35 in total

1.  Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.

Authors:  Nisanne S Ghonem; Meenakshisundaram Ananthanarayanan; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

2.  The flip side of cardiolipin import.

Authors:  Coen C Paulusma; Roderick H J Houwen; Patrick L Williamson
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440

Review 3.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

Review 4.  Progressive familial intrahepatic cholestasis.

Authors:  Anshu Srivastava
Journal:  J Clin Exp Hepatol       Date:  2013-11-23

5.  Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.

Authors:  Shi-Ying Cai; Xinshou Ouyang; Yonglin Chen; Carol J Soroka; Juxian Wang; Albert Mennone; Yucheng Wang; Wajahat Z Mehal; Dhanpat Jain; James L Boyer
Journal:  JCI Insight       Date:  2017-03-09

6.  Strain background modifies phenotypes in the ATP8B1-deficient mouse.

Authors:  Sohela Shah; Ukina R Sanford; Julie C Vargas; Hongmei Xu; Annamiek Groen; Coen C Paulusma; James P Grenert; Ludmila Pawlikowska; Saunak Sen; Ronald P J Oude Elferink; Laura N Bull
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

Review 7.  Bile acid transporters.

Authors:  Paul A Dawson; Tian Lan; Anuradha Rao
Journal:  J Lipid Res       Date:  2009-06-04       Impact factor: 5.922

8.  Phospholipid flippase activities and substrate specificities of human type IV P-type ATPases localized to the plasma membrane.

Authors:  Hiroyuki Takatsu; Gaku Tanaka; Katsumori Segawa; Jun Suzuki; Shigekazu Nagata; Kazuhisa Nakayama; Hye-Won Shin
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

9.  Phospholipase D2 mediates signaling by ATPase class I type 8B membrane 1.

Authors:  Frank Chen; Ayantika Ghosh; Benjamin L Shneider
Journal:  J Lipid Res       Date:  2012-12-04       Impact factor: 5.922

10.  Control of protein and sterol trafficking by antagonistic activities of a type IV P-type ATPase and oxysterol binding protein homologue.

Authors:  Baby-Periyanayaki Muthusamy; Sumana Raychaudhuri; Paramasivam Natarajan; Fumiyoshi Abe; Ke Liu; William A Prinz; Todd R Graham
Journal:  Mol Biol Cell       Date:  2009-04-29       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.